Vaccine Effectiveness Against SARS-CoV-2 Infection and Severe Outcomes in the Maintenance Dialysis Population in Ontario, Canada.
COVID-19
Ontario
SARS-CoV-2
chronic dialysis
hospitalization
maintenance
mortality
Journal
Journal of the American Society of Nephrology : JASN
ISSN: 1533-3450
Titre abrégé: J Am Soc Nephrol
Pays: United States
ID NLM: 9013836
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
23
09
2021
accepted:
04
02
2022
pubmed:
11
3
2022
medline:
5
4
2022
entrez:
10
3
2022
Statut:
ppublish
Résumé
Vaccination studies in the hemodialysis population have demonstrated decreased antibody response compared with healthy controls, but vaccine effectiveness for preventing SARS-CoV-2 infection and severe disease is undetermined. We conducted a retrospective cohort study in the province of Ontario, Canada, between December 21, 2020, and June 30, 2021. Receipt of vaccine, SARS-CoV-2 infection, and related severe outcomes (hospitalization or death) were determined from provincial health administrative data. Receipt of one and two doses of vaccine were modeled in a time-varying cause-specific Cox proportional hazards model, adjusting for baseline characteristics, background community infection rates, and censoring for non-COVID death, recovered kidney function, transfer out of province, solid organ transplant, and withdrawal from dialysis. Among 13,759 individuals receiving maintenance dialysis, 2403 (17%) were unvaccinated and 11,356 (83%) had received at least one dose by June 30, 2021. Vaccine types were BNT162b2 ( COVID-19 vaccination is effective in the dialysis population to prevent SARS-CoV-2 infection and severe outcomes, despite concerns about suboptimal antibody responses.
Sections du résumé
BACKGROUND
Vaccination studies in the hemodialysis population have demonstrated decreased antibody response compared with healthy controls, but vaccine effectiveness for preventing SARS-CoV-2 infection and severe disease is undetermined.
METHODS
We conducted a retrospective cohort study in the province of Ontario, Canada, between December 21, 2020, and June 30, 2021. Receipt of vaccine, SARS-CoV-2 infection, and related severe outcomes (hospitalization or death) were determined from provincial health administrative data. Receipt of one and two doses of vaccine were modeled in a time-varying cause-specific Cox proportional hazards model, adjusting for baseline characteristics, background community infection rates, and censoring for non-COVID death, recovered kidney function, transfer out of province, solid organ transplant, and withdrawal from dialysis.
RESULTS
Among 13,759 individuals receiving maintenance dialysis, 2403 (17%) were unvaccinated and 11,356 (83%) had received at least one dose by June 30, 2021. Vaccine types were BNT162b2 (
CONCLUSIONS
COVID-19 vaccination is effective in the dialysis population to prevent SARS-CoV-2 infection and severe outcomes, despite concerns about suboptimal antibody responses.
Identifiants
pubmed: 35264455
pii: 00001751-202204000-00017
doi: 10.1681/ASN.2021091262
pmc: PMC8970446
doi:
Substances chimiques
COVID-19 Vaccines
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
839-849Informations de copyright
Copyright © 2022 by the American Society of Nephrology.
Références
Taji L, Thomas D, Oliver MJ, Ip J, Tang Y, Yeung A, et al.: COVID-19 in patients undergoing long-term dialysis in Ontario. Can Med Assoc J 193: E278–E284, 2021
Hsu CM, Weiner DE, Aweh G, Miskulin DC, Manley HJ, Stewart C, et al.: COVID-19 among US dialysis patients: Risk factors and outcomes from a national dialysis provider. Am J Kidney Dis 77: 748–756.e1, 2021
Jager KJ, Kramer A, Chesnaye NC, Couchoud C, Sánchez-Álvarez JE, Garneata L, et al.: Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe. Kidney Int 98: 1540–1548, 2020
Couchoud C, Bayer F, Ayav C, Béchade C, Brunet P, Chantrel F, et al.; French REIN registry: Low incidence of SARS-CoV-2, risk factors of mortality and the course of illness in the French national cohort of dialysis patients. Kidney Int 98: 1519–1529, 2020
Blake PG, Hladunewich MA, Oliver MJ: COVID-19 vaccination imperatives in people on maintenance dialysis: An international perspective. Clin J Am Soc Nephrol 16: 1746–1748, 2021
Goupil R, Benlarbi M, Beaubien-Souligny W, Nadeau-Fredette AC, Chatterjee D, Goyette G, et al.; Réseau Rénal Québécois (Quebec Renal Network) COVID-19 Study Investigators: Short-term antibody response after 1 dose of BNT162b2 vaccine in patients receiving hemodialysis. CMAJ 193: E793–E800, 2021
Yau K, Abe KT, Naimark D, Oliver MJ, Perl J, Leis JA, et al.: Evaluation of the SARS-CoV-2 antibody response to the BNT162b2 vaccine in patients undergoing hemodialysis. JAMA Netw Open 4: e2123622, 2021
Grupper A, Sharon N, Finn T, Cohen R, Israel M, Agbaria A, et al.: Humoral response to the Pfizer BNT162b2 vaccine in patients undergoing maintenance hemodialysis. Clin J Am Soc Nephrol 16: 1037–1042, 2021
Simon B, Rubey H, Treipl A, Gromann M, Hemedi B, Zehetmayer S, et al.: Haemodialysis patients show a highly diminished antibody response after COVID-19 mRNA vaccination compared with healthy controls. Nephrol Dial Transplant 36: 1709–1716, 2021
Schrezenmeier E, Bergfeld L, Hillus D, Lippert JD, Weber U, Tober-Lau P, et al.: Immunogenicity of COVID-19 Tozinameran vaccination in patients on chronic dialysis. Front Immunol 12: 690698, 2021
Yanay NB, Freiman S, Shapira M, Wishahi S, Hamze M, Elhaj M, et al.: Experience with SARS-CoV-2 BNT162b2 mRNA vaccine in dialysis patients. Kidney Int 99: 1496–1498, 2021
Broseta JJ, Rodríguez-Espinosa D, Rodríguez N, Mosquera MDM, Marcos MÁ, Egri N, et al.: Humoral and cellular responses to mRNA-1273 and BNT162b2 SARS-CoV-2 vaccines administered to hemodialysis patients. Am J Kidney Dis 78: 571–581, 2021
Sibbel S, McKeon K, Luo J, Wendt K, Walker AG, Kelley T, et al.: Real-world effectiveness and immunogenicity of BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines in patients on hemodialysis. J Am Soc Nephrol 33: 49–57, 2022
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al.; C4591001 Clinical Trial Group: Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med 383: 2603–2615, 2020
Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al.; COVE Study Group: Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 384: 403–416, 2021
Chung H, He S, Nasreen S, Sundaram ME, Buchan SA, Wilson SE, et al.; Canadian Immunization Research Network (CIRN) Provincial Collaborative Network (PCN) Investigators: Effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes in Ontario, Canada: Test negative design study. BMJ 374: n1943, 2021
Ontario Renal Network OH: Ontario Renal Reporting System (ORRS) Release 8 (R8) Data Dictionary. Available at: https://ext.cancercare.on.ca/ext/databook/db1920/documents/Appendix/ORRS_Release_8_(R8)_Data_Dictionary_V3.pdf . Accessed September 1, 2021
www.publichealthontario.ca: All Ontario: Case numbers and spread. Available at: https://covid-19.ontario.ca/data/case-numbers-and-spread . Accessed September 1, 2021
Statistics Canada: Canadian Index of Multiple Deprivation: Dataset and User Guide. Available at: https://www150.statcan.gc.ca/n1/en/catalogue/45200001 . Accessed September 1, 2021
Austin PC: Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul Comput 38: 1228–1234, 2009
Yang D, Dalton JE: A unified approach to measuring the effect size between two groups using SAS. SAS Global Forum. Stat Data Anal paper 335-2012, 1–6, 2012
Shrotri M, Krutikov M, Palmer T, Giddings R, Azmi B, Subbarao S, et al.: Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): A prospective cohort study. Lancet Infect Dis 21: 1529–1538, 2021
Khan N, Mahmud N: Effectiveness of SARS-CoV-2 vaccination in a Veterans Affairs cohort of patients with inflammatory bowel disease with diverse exposure to immunosuppressive medications. Gastroenterology 161: 827–836, 2021
Tartof SY, Slezak JM, Fischer H, Hong V, Ackerson BK, Ranasinghe ON, et al.: Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: A retrospective cohort study. Lancet 398: 1407–1416, 2021
Wolkewitz M, Cooper BS, Palomar-Martinez M, Alvarez-Lerma F, Olaechea-Astigarraga P, Barnett AG, et al.: Multiple time scales in modeling the incidence of infections acquired in intensive care units. BMC Med Res Methodol 16: 116, 2016
Thompson MG, Burgess JL, Naleway AL, Tyner H, Yoon SK, Meece J, et al.: Prevention and attenuation of COVID-19 with the BNT162b2 and mRNA-1273 vaccines. N Engl J Med 385: 320–329, 2021
Austin PC, Hux JE: A brief note on overlapping confidence intervals. J Vasc Surg 36: 194–195, 2002
Attias P, Sakhi H, Rieu P, Soorkia A, Assayag D, Bouhroum S, et al.: Antibody response to the BNT162b2 vaccine in maintenance hemodialysis patients. Kidney Int 99: 1490–1492, 2021
Agur T, Ben-Dor N, Goldman S, Lichtenberg S, Herman-Edelstein M, Yahav D, et al.: Antibody response to mRNA SARS-CoV-2 vaccine among dialysis patients—A prospectivecohort study [published online ahead of print April 11, 2021]. Nephrol Dial Transplant
Anand S, Montez-Rath ME, Han J, Garcia P, Cadden L, Hunsader P, et al.: Antibody response to COVID-19 vaccination in patients receiving dialysis. J Am Soc Nephrol 32: 2435–2438, 2021
Yau K, Muller MP, Lin M, Siddiqui N, Neskovic S, Shokar G, et al.: COVID-19 outbreak in an urban hemodialysis unit. Am J Kidney Dis 76: 690–695.e1, 2020
Camerino M, Jackson S, Chinnakotla S, Verghese P: Effects of the influenza vaccine on pediatric kidney transplant outcomes. Pediatr Transplant 23: e13354, 2019
Austin PC, Latouche A, Fine JP: A review of the use of time-varying covariates in the Fine-Gray subdistribution hazard competing risk regression model. Stat Med 39: 103–113, 2020
Lau B, Cole SR, Gange SJ: Competing risk regression models for epidemiologic data. Am J Epidemiol 170: 244–256, 2009
Poguntke I, Schumacher M, Beyersmann J, Wolkewitz M: Simulation shows undesirable results for competing risks analysis with time-dependent covariates for clinical outcomes. BMC Med Res Methodol 18: 79, 2018
Beyersmann J, Schumacher M: Time-dependent covariates in the proportional subdistribution hazards model for competing risks. Biostatistics 9: 765–776, 2008
Public Health Ontario: COVID-19 variants of concern in Ontario: December 1, 2020 to May 9, 2021. 2021. Available at: https://www.publichealthontario.ca/-/media/documents/ncov/epi/covid-19-variant-epi-summary.pdf . Accessed July 17, 2021